Home » Newsletters » BioWorld Science

BioWorld Science

June 7, 2002

View Archived Issues

Gabapentin receptor ligands presented by Gruenenthal

Esperion claims ether compounds for use in lipoprotein disorders, etc.

Novel vitronectin antagonist and use in osteoporosis disclosed by Aventis and Genentech

New CCR3 antagonists in the Novartis pipeline

Merck researchers identify new gamma-secretase inhibitors for AD

AstraZeneca presents novel Src kinase inhibitors

Maximum tolerated dose identified for AP-5280

AES-14 reduces severe mucositis in acute radiation model

Actelion presents key pipeline highlights

New antiatherosclerotic compounds claimed by Servier

Launch of Remodulin expands treatment options for pulmonary hypertension

Promising phase I results with ISF-154 lead to initiation of phase II trial in CLL

Phase III trial of RSR-13 in brain metastases continues following interim review

Effects of mepolizumab on allergen-induced late-phase skin reaction studied in atopic asthmatics

New class of orally active, selective V1a receptor antagonists designed by Japanese lab

Isoquinoline alkaloids identified by Korean scientists as having potential in septic shock

Acceptable safety and PK profile emerges from ongoing phase I trial of EKB-569

A phase I trial in patients with advanced solid tumors shows the safety and efficacy of BMS-214662

Phase II dose of orally active MEK inhibitor selected from phase I studies

New indications approved for desloratadine in E.U.

Nasal apomorphine set to enter phase I trials for erectile dysfunction

FDA issues approvable letter for Crestor

ING-1 suitable for further evaluation according to initial human study

Phase Ib trial evaluating CA4P in combination with carboplatin in advanced solid tumors

FluINsure cleared for phase II testing in influenza

PI-88 plus Taxotere to be evaluated in phase I trial

Corixa initiates U.S. study of PVAC in mild to moderate plaque psoriasis